Rocket Pharmaceuticals, Inc.
RCKT
$4.87
$0.142.96%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 13.77% | 6.65% | -1.60% | -3.49% | -5.35% |
| Total Depreciation and Amortization | 17.60% | 24.81% | 24.03% | 31.66% | 32.08% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -10.68% | 14.11% | 19.22% | 5.75% | 14.17% |
| Change in Net Operating Assets | -245.71% | -127.64% | -59.37% | -63.94% | -58.97% |
| Cash from Operations | 9.40% | -5.20% | -3.36% | -7.44% | -7.60% |
| Capital Expenditure | 92.49% | 93.44% | 82.58% | 72.88% | 64.33% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -24.25% | -22.66% | 50.21% | 494.55% | 268.53% |
| Cash from Investing | -21.21% | 2.43% | 880.45% | 246.85% | 234.30% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 5,472.97% | -4.97% | -3.50% | -10.87% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -99.92% | 5,477.48% | -4.85% | -3.50% | -10.87% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -179.93% | 106.47% | 10.57% | 149.64% | 227.36% |